AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03633643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)
Description: five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day~1 and 2 after surgery while the patient is in hospital.
Study NCT03633643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral applications of Placebo
Description: five oral applications of Placebo at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
Study NCT03201328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audio-vestibular examination
Description: Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.
Study NCT03201328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio-vestibular examination
Description: Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.
Study NCT03201328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videonystagmoscopic study
Description: Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.
Study NCT03201328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videonystagmoscopic study
Description: Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.
Study NCT03201328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posturographies study
Description: (stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.
Study NCT03201328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posturographies study
Description: (stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.
Study NCT02817542 — intervention group
Intervention type: DEVICE
Intervention: percutaneous coronary intervention
Description: Percutaneous coronary intervention. Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion. A minimum of two syringes (40 mL) of aspirate will be recommended. The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter. The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus. PCI procedure will be done without thrombectomy as per the investigator. Direct stenting will not be mandated in either treatment group. Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy. The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.
Study NCT01236222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling to school
Description: Regular cycling to school
Study NCT05416606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral bipolar enucleation and resection of the prostate
Description: transurethral bipolar enucleation and resection of the prostate
Study NCT05416606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgical transvesical prostatectomy
Description: open surgical transvesical prostatectomy
Study NCT01380756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1- Dose Escalation
Description: AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
Study NCT01380756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 2- Dose Expansion
Description: AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
Study NCT03025191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speaker/Listener technique
Description: Couple will learn taking turns as the speaker and as the listener who paraphrases the speaker's point.The couple will then identify an issue they have faced in their relationship and will role-play using the technique to discuss it.
Study NCT03025191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Identification of and mapping sources of social support and the types of support provided by members of the network. Participants will also identify the strengths and weaknesses of their support network and think through ways to strengthen those networks.
Study NCT03025191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving
Description: Couple will be taught steps to systematically analyze a problem and brainstorm solutions through a short video. Steps include identify the trigger/problem; identify the goal for addressing the problem; brainstorm possible solutions for each partner; evaluate the solutions and pick the best; and act on the best solution.
Study NCT03025191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Couple will be introduced to the concept of short- and long-term goal setting, including components of goal and planning for potential barriers. The couple will then set a goal for themselves that incorporates the skills obtained during the intervention, such as strengthening ties in their social support network. Participants will fill in a worksheet outlining their goal, potential barriers, and solutions to those barriers.
Study NCT03687177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: With visual cue and nurses informed
Description: Using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
Study NCT03687177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Without visual cue and nurses informed
Description: Not using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
Study NCT00675285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: one tablet 5 mg once/day for 4 weeks
Study NCT01272219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
Study NCT00214526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty with the Alair System
Description: Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
Study NCT00214526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy with ICS+LABA
Description: Conventional therapy with ICS+LABA.
Study NCT03729141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Added Cholesterol
Description: Participants assigned to the added cholesterol group will receive snacks containing added cholesterol (1g/day) for 3 weeks prior to surgery.
Study NCT03729141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Added Cholesterol
Description: Participants assigned to the no added cholesterol group will receive snacks containing no added cholesterol for 3 weeks prior to surgery.
Study NCT03375164 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec.
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexrazoxane hydrochloride
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: Given orally
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study NCT00400946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IV
Study NCT00994487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Energy Density Preload
Description: Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is high in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles
Study NCT00994487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Energy Density Preload
Description: Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is low in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles.
Study NCT00994487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Energy Density Preload
Description: Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is low in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles.
Study NCT03735810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBS-008
Description: LBS-008 oral capsules
Study NCT03735810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral capsules
Study NCT01238783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension
Description: Topical ocular dosed 3 times per day for 3 days
Study NCT01238783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-15469A 0.5%
Description: Topical ocular dosed 3 times per day for 3 days
Study NCT01238783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-6515 0.3%
Description: Topical ocular dosed 3 times per day for 3 days
Study NCT01238783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical ocular dosed 3 times per day for 3 days
Study NCT00619476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 1200mg/day
Description: gabapentin enacarbil 1200mg/day
Study NCT00619476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 2400mg/day
Description: gabapentin enacarbil 2400mg/day
Study NCT00619476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 3600mg/day
Description: gabapentin enacarbil 3600mg/day
Study NCT00619476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01300429 — intervention group
Intervention type: GENETIC
Intervention: obtain tissue specimens
Description: One core biopsy specimen will be placed in formalin and processed for cytogenetic and FISH analyses as well as DNA for ALK sequencing. The second core biopsy specimen will be immediately frozen in liquid nitrogen and stored in a -80 degree freezer for research specimen. Collection will be performed on-site at the time of the procedure.
Study NCT02259920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KUC 7483 CL, immediate release tablet
Study NCT02259920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL, particulate formulation
Study NCT02259920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL, solution formulation
Study NCT02259920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterion™ capsule
Study NCT01336062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle Albumin-Bound Paclitaxel
Description: this study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
Study NCT02169830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nortriptyline
Description: The nortriptyline will be given in an escalating fashion, starting at 25 mg PO qhs for 2 weeks, followed by 50 mg PO qhs for 2 weeks, and finally 75 mg PO qhs. Patients will be encouraged to use the lowest effective dose and to self-titrate their medication.
Study NCT02169830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate dosing will be 25 mg PO qhs for 1 week, followed by 25 mg BID for 1 week, followed by 25 mg in the morning and 50 mg qhs for 1 week, and finally 50 mg BID
Study NCT02169830 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet Modification
Description: Emphasis will be given to cessation of known migraine triggers such as caffeine, sodas, chocolates, alcohol (especially red wine) and aged cheeses. Patients who have complete control of their symptoms with diet and behavior modification alone will be followed for a total of 4 months to determine the durability of symptom relief.
Study NCT00968838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: White Blood Cell Transfusion
Description: 4 Transfusions, each taking approximately 1 hour:~Patients \<50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions.~Patients >50 years of age are randomized to receive either radiated or non radiated transfusions.
Study NCT00742885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Description: All subjects will receive 2 doses administered as an intramuscular (IM) injection.
Study NCT04049201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elective surgery
Description: investigators will compare the effect of interactive tablet on preoperative anxiety in children to the effect ofMidazolam in elective surgery
Study NCT04049201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: elective surgery
Description: investigators will compare the effect of interactive tablet on preoperative anxiety in children to the effect ofMidazolam in elective surgery
Study NCT04049201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Oral Midazolam
Study NCT04049201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive Tablet
Description: interactive Tablet containing many cartoon's videos
Study NCT03055585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wolbachia-infected Aedes aegypti mosquitoes
Description: Deployment of Wolbachia-infected Aedes aegypti mosquitoes
Study NCT03055585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard practice dengue control
Description: standard practice dengue control activities conducted by dengue control program
Study NCT03055585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard practice dengue control
Description: standard practice dengue control activities conducted by dengue control program
Study NCT00798395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 50081
Description: 1.5 mg on day 1-7
Study NCT00798395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 50081
Description: 4.5 mg on Day 1-7
Study NCT00798395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily on Day 1-7
Study NCT00798395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zopiclone
Description: Single dose of 7.5 mg
Study NCT03038074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Oximeter with respiration rate sensor
Study NCT02174198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioOss Collagen at the time of implant placement
Description: Experimental: placement of BioOss Collagen No intervention: no BioOss Collagen
Study NCT03049982 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Auto-titrating mandibular positioner test
Description: Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
Study NCT01548443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medifoam H dressing
Description: Cover medifoam H on the wound for a week.
Study NCT01548443 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duoderm THIN dressing
Description: Cover Duoderm THIN on the wound for a week
Study NCT01710293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication of Patients Lost to Follow-up to Providers
Description: The investigators will query the VA's database weekly to identify possible lost to follow-up events for a random sample of about half of the providers at our study sites. The queries will use the trigger criteria developed in our previous work for colorectal cancer, lung cancer, hepatocellular carcinoma, breast cancer, and bladder cancer. The list of trigger positive patients will be transmitted to a facility-level recipient who will either disseminate the information to existing facility individual cancer care coordinators/trackers or will review the charts of the triggered patients in order to determine whether these patients have been truly lost to follow-up or not. If patients are found to be lost to follow-up, the Facility Recipient or cancer care coordinator/tracker will communicate the need for follow-up to the PACT or primary care provider, using secure emails, phone calls, or in person, depending on which method of communication they deem most appropriate and effective.
Study NCT02377765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Stimulation
Description: TPTNS through a TENS unit is a non-invasive technique, easily manageable by patients, which lacks some adverse side effects reported with the use of PTNS, such as bleeding and/or pain at the site of needle insertion. As the technique is self-administered, the associated costs might be substantially lower when compared to PTNS, which involves repeated Hospital appointments for maintenance therapy.
Study NCT02377765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneus Stimulation
Description: PTNS aims to stimulate the sacral nerve plexus (origin to the parasympathetic innervations to the bladder) through the afferent fibres of the posterior tibial nerve, a mixed nerve containing L5-S3 fibres (Slovak, Chapple and Barker, 2014). This is achieved by a needle electrode inserted above the medial malleolus. Interestingly, this anatomical area is known as acupuncture point Spleen6 (Sp6).
Study NCT02419547 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Versed
Description: Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
Study NCT02419547 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl
Description: Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
Study NCT02419547 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Phase 2: Standard induction of GETA with intravenous agent then programed stimulation to induce ventricular tachycardia
Study NCT02419547 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: Phase 3: Standard induction of GETA with inhalent agent then programed stimulation to induce ventricular tachycardia
Study NCT02754609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten micro-challenge
Description: From week 12 to week 24, all participants will start a gluten micro-challenge from 10mg/day for the first 2 weeks escalating over the this period to 50mg/day at the end of week 24.